Results 161 to 170 of about 171,612 (313)

The role of nucleic acid sensors in antifungal immunity. [PDF]

open access: yesFront Immunol
Liang X, Zhou H, Ouyang L, Chen J, He W.
europepmc   +1 more source

Interferon‐Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
Triple‐negative breast cancer exhibits variable sensitivity to PRMT5 inhibition. Basal interferon signaling is identified as a key biomarker of response. PARP inhibition with olaparib induces IFN signaling, sensitizing resistant TNBC cells to PRMT5 inhibitors.
Ziwen Zhang   +9 more
wiley   +1 more source

FAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD‐L1 and T Cell Senescence

open access: yesAdvanced Science, EarlyView.
ABSTRACT Multiple myeloma (MM) is a hematologic malignancy driven by clonal expansion of malignant plasma cells. Despite the long‐term disease control achieved with immunotherapies in some patients, treatment resistance remains a major cause of disease relapse.
Huiyao Gu   +15 more
wiley   +1 more source

Toll-like Receptor 3–Mediated Suppression of TRAMP Prostate Cancer Shows the Critical Role of Type I Interferons in Tumor Immune Surveillance [PDF]

open access: bronze, 2010
Arnold I. Chin   +6 more
openalex   +1 more source

Inhibition of Hypersialylation in Human Intervertebral Disc Degeneration Modulates Inflammation and Metabolism

open access: yesAdvanced Science, EarlyView.
Glycosylation, specifically hypersialylation, is identified as a critical factor in human intervertebral disc (IVD) degeneration—a major cause of low back pain. This study demonstrates that inhibiting sialylation reduces inflammation and oxidative stress in IVD tissues, suggesting new therapeutic possibilities.
Kieran Joyce   +8 more
wiley   +1 more source

Computational Design and Glycoengineering of Interferon‐Lambda for Nasal Prophylaxis Against Respiratory Viruses

open access: yesAdvanced Science, EarlyView.
This study presents an engineered human interferon‐lambda (hIFN‐λ) as an intranasal prophylactic against respiratory viruses. By combining AI‐guided backbone redesign and glycoengineering, the authors developed a thermostable, protease‐resistant, and scalable variant with improved mucosal penetration.
Jeongwon Yun   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy